CMN Weekly (21 February 2025) - Your Weekly CRISPR...
CMN Weekly
Feb. 21, 2025
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
ASC Therapeutics
Company Type: Therapeutic development
Main focus: Developing curative treatments for various diseases through a proprietary gene-editing platform, TARGATT™, and other gene-editing technologies
Company stage: Clinical
Diseases: β-Thalassemia, haemophilia, and graft-versus-host disease
Genome-editing tool: CRISPR-Cas9 and TARGATT™
Funding stage: Private
Location: Milpitas, California, USA
Website: https://www.asctherapeutics.com/
Pipeline: https://www.asctherapeutics.com/our-pipeline/
Partners: University of Massachusetts, University of Pennsylvania, Stanford University, Emory University, Shantou University, Peking University Shenzhen Hospital
ASC Therapeutics is a biotechnology company focused on developing gene therapies for rare genetic disorders. The company uses advanced CRISPR gene editing and gene replacement technologies to create treatments for diseases such as haemophilia A and B, β-thalassemia, and other monogenic conditions. ASC Therapeutics has so far disclosed three pre-clinical-stage gene-editing programmes.
